, formerly Venator and before that Woolworth, reported third-quarter earnings, before items, of 26 cents a share, meeting analysts' estimates. Sales totaled $1.08 billion. Same-store sales rose 5.6%. The company projected earnings of 25 cents to 30 cents a share for the fourth quarter and income of 95 cents to $1 a share for the year. Analysts expect earnings of 30 cents in the quarter and $1 for the year.
Earnings Reports & Warnings
reported a loss of 14 cents a share for the third quarter, missing estimates by a penny. Sales rose 5.4% to $773.1 million. Comparable-store sales for stores open two years at the beginning of the fiscal year were flat for the quarter. The closeout retailer estimated that fourth-quarter earnings will be in the range of 50 cents a share, while analysts are looking for income of 55 cents.
posted a third-quarter loss of $1.07 a share. Third-quarter sales fell 8.3% to $58.5 million, and same-store sales dropped 17% from last year.
earned 35 cents a share in the latest first fiscal quarter, matching Wall Street's estimates. The restaurant group said revenue rose 6% to $495.2 million. For the second quarter, the company expects earnings to grow at least 15% from the same period a year ago, when CBRL brought in 26 cents a share. That guidance would imply income of about 30 cents a share, which would be a penny shy of estimates, according to First Call.
lost 48 cents a share in the third fiscal quarter. Analysts were calling for a loss of 42 cents. The department store owner said sales for the quarter fell 5% to $1.87 billion. Same-store sales decreased 6%.
reported disappointing results from a Phase III trial evaluating tifacogin in severe sepsis. The results from the trial indicate that tifacogin didn't meet the primary goal of reducing 28-day mortality. The company said there weren't any safety issues identified in the patients who took the treatment. Tifacogin is being developed by Chiron and
Salomon Smith Barney downgraded
to neutral from outperform based on the stock's valuation. The firm said the shares are trading at the high end of the historical price-to-earnings and price-to-sales ranges, despite declining margins and a lower growth rate. Salomon also said estimates for the March and June quarters might be too aggressive because of weakness in Japan and Europe.
After Tuesday's Close
provided Wall Street with an optimistic forecast for 2002. The company said it expects earnings per share to grow in the low-20% range in 2002. Analysts are expecting the company to post earnings of $1.19 a share this year and $1.40 in 2002. Earnings growth of even 20% implies a bottom line of about $1.43 for next year. The forecast excludes the effects of a possible new application for Aranesp and pegfilgrastim, a long-acting version of Neupogen.
topped fourth-quarter estimates, but guided Wall Street lower. The company posted fourth-quarter earnings of 14 cents a share, 2 cents ahead of estimates. Revenue totaled $423 million, but the company expects the top line to drop 5% in the first fiscal quarter. Analog also projected earnings of 11 cents a share for the quarter, while analysts are looking for 15 cents.
forecast fourth-quarter revenue at the low end of its previous $75 million to $80 million range. The chipmaker also said it expects to earn 4 cents a share in the quarter, in line with analysts' estimates, although at the low end of its own previously issued guidance. The estimate excludes an expected $100 million charge related to excess capacity.